{"title":"Risk factors for complications after cytoreductive surgery (CRS) and HIPEC in 290 peritoneal malignancies of primary and secondary origins.","authors":"Ludovico Carbone, Gianmario Edoardo Poto, Aurora Visani, Riccardo Mainenti, Marta Fasulo, Eleonora Andreucci, Engjell Kelmendi, Stefania Piccioni, Irene Crecchi, Giovanna Gallucci, Lucia Bobbio, Zhouqiao Wu, Salvatora Tindara Miano, Roberto Petrioli, Franco Roviello, Daniele Marrelli","doi":"10.1007/s13304-026-02839-9","DOIUrl":null,"url":null,"abstract":"<p><p>Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is effective for selected peritoneal malignancies but carries potential postoperative morbidity. Defining complication rates, severity and predictors is crucial to optimize management, patient selection, and risk stratification. A retrospective observational study was conducted including patients with primary or secondary peritoneal surface malignancies who underwent CRS-HIPEC between 2002 and 2025. Postoperative complications were graded according to CTCAE and Clavien-Dindo classifications. Early postoperative renal function was evaluated in a select cohort receiving sodium thiosulfate nephroprotection. A total of 290 patients were included (median age 60 years, PCI 5). Standard-extended peritonectomy was performed in 167 (57.6%) cases, and multivisceral resection in 27 (10.7%). Optimal debulking was achieved in 263 (90.7%). Postoperative complications occurred in 51.7%, medical and chemotherapy-related complications in 45.5% and surgical ones in 12.4% of cases. Postoperative anemia was common (32.7%), predominantly at CTCAE Grade 3. Severe complications, graded as 3-5 according to ClavienDindo score, occurred in 11.7%, mainly in elderly (20.4% vs. 9.7%, p = 0.090), with no 30-day mortality. Older age, higher comorbidity burden and splenectomy emerged as predictors of severe complications. In 22 patients receiving sodium thiosulfate, creatinine and urine output were significantly lower on postoperative day 5-7, suggesting a renal protective effect. Overall, 3-year survival was 62.2%. Anastomotic fistula (HR 2.43, p = 0.015), surgical site infection (1.81, p = 0.070), and thrombocytopenia (3.64, p < 0.001) were independent negative prognostic factors. CRS and HIPEC can be performed with acceptable morbidity and low mortality in specialized center. Further efforts to reduce complications are essential to improve postoperative outcomes and overall prognosis.</p>","PeriodicalId":23391,"journal":{"name":"Updates in Surgery","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Updates in Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13304-026-02839-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
Abstract
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is effective for selected peritoneal malignancies but carries potential postoperative morbidity. Defining complication rates, severity and predictors is crucial to optimize management, patient selection, and risk stratification. A retrospective observational study was conducted including patients with primary or secondary peritoneal surface malignancies who underwent CRS-HIPEC between 2002 and 2025. Postoperative complications were graded according to CTCAE and Clavien-Dindo classifications. Early postoperative renal function was evaluated in a select cohort receiving sodium thiosulfate nephroprotection. A total of 290 patients were included (median age 60 years, PCI 5). Standard-extended peritonectomy was performed in 167 (57.6%) cases, and multivisceral resection in 27 (10.7%). Optimal debulking was achieved in 263 (90.7%). Postoperative complications occurred in 51.7%, medical and chemotherapy-related complications in 45.5% and surgical ones in 12.4% of cases. Postoperative anemia was common (32.7%), predominantly at CTCAE Grade 3. Severe complications, graded as 3-5 according to ClavienDindo score, occurred in 11.7%, mainly in elderly (20.4% vs. 9.7%, p = 0.090), with no 30-day mortality. Older age, higher comorbidity burden and splenectomy emerged as predictors of severe complications. In 22 patients receiving sodium thiosulfate, creatinine and urine output were significantly lower on postoperative day 5-7, suggesting a renal protective effect. Overall, 3-year survival was 62.2%. Anastomotic fistula (HR 2.43, p = 0.015), surgical site infection (1.81, p = 0.070), and thrombocytopenia (3.64, p < 0.001) were independent negative prognostic factors. CRS and HIPEC can be performed with acceptable morbidity and low mortality in specialized center. Further efforts to reduce complications are essential to improve postoperative outcomes and overall prognosis.
细胞减少手术(CRS)与腹腔内高温化疗(HIPEC)是有效的选择腹膜恶性肿瘤,但有潜在的术后发病率。确定并发症发生率、严重程度和预测因素对于优化管理、患者选择和风险分层至关重要。一项回顾性观察研究纳入了2002年至2025年间接受CRS-HIPEC的原发性或继发性腹膜表面恶性肿瘤患者。根据CTCAE和Clavien-Dindo分类对术后并发症进行分级。在接受硫代硫酸钠肾保护的队列中,对术后早期肾功能进行评估。共纳入290例患者(中位年龄60岁,PCI 5)。167例(57.6%)行标准扩展腹膜切除术,27例(10.7%)行多脏器切除术。263例(90.7%)达到最佳减体积。术后并发症占51.7%,药物及化疗相关并发症占45.5%,手术并发症占12.4%。术后贫血很常见(32.7%),主要是CTCAE 3级。严重并发症发生率为11.7%,ClavienDindo评分为3-5级,主要发生在老年人(20.4% vs. 9.7%, p = 0.090),无30天死亡率。年龄较大、较高的合并症负担和脾切除术成为严重并发症的预测因素。在22例接受硫代硫酸钠治疗的患者中,术后第5-7天肌酐和尿量明显降低,提示其有肾保护作用。总体而言,3年生存率为62.2%。吻合口瘘(HR 2.43, p = 0.015)、手术部位感染(HR 1.81, p = 0.070)、血小板减少(HR 3.64, p = 0.015)
期刊介绍:
Updates in Surgery (UPIS) has been founded in 2010 as the official journal of the Italian Society of Surgery. It’s an international, English-language, peer-reviewed journal dedicated to the surgical sciences. Its main goal is to offer a valuable update on the most recent developments of those surgical techniques that are rapidly evolving, forcing the community of surgeons to a rigorous debate and a continuous refinement of standards of care. In this respect position papers on the mostly debated surgical approaches and accreditation criteria have been published and are welcome for the future.
Beside its focus on general surgery, the journal draws particular attention to cutting edge topics and emerging surgical fields that are publishing in monothematic issues guest edited by well-known experts.
Updates in Surgery has been considering various types of papers: editorials, comprehensive reviews, original studies and technical notes related to specific surgical procedures and techniques on liver, colorectal, gastric, pancreatic, robotic and bariatric surgery.